

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claims 1-99 (canceled).

Claim 100 (new): A hapten-carrier conjugate comprising at least one hapten derived from nicotine and at least one carrier containing a T cell epitope and wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	$(\text{CH}_2)_n\text{Q}$
CJ 1.1	CO_2Q
CJ 1.2	COQ
CJ 1.3	OCH_3
CJ 2	$\text{OCO}(\text{CH}_2)_n\text{Q}$
CJ 2.1	$\text{OCOCH}=\text{Q}$
CJ 2.2	$\text{OCOCH}(\text{O})\text{CH}_2$
CJ 2.3	$\text{OCO}(\text{CH}_2)_n\text{CH}(\text{O})\text{CH}_2$
CJ 3	$\text{CO}(\text{CH}_2)_n\text{COQ}$
CJ 3.1	$\text{CO}(\text{CH}_2)_n\text{CNQ}$
CJ 4	$\text{OCO}(\text{CH}_2)_n\text{COQ}$
CJ 4.1	$\text{OCO}(\text{CH}_2)_n\text{CNQ}$
CJ 5	$\text{CH}_2\text{OCO}(\text{CH}_2)_n\text{COQ}$
CJ 5.1	$\text{CH}_2\text{OCO}(\text{CH}_2)_n\text{CNQ}$
CJ 6	$\text{CONH}(\text{CH}_2)_n\text{Q}$
CJ 7	$\text{Y}(\text{CH}_2)_n\text{Q}$
CJ 7.1	$\text{CH}_2\text{Y}(\text{CH}_2)_n\text{Q}$
CJ 8	$\text{OCOCH}(\text{OH})\text{CH}_2\text{Q}$
CJ 8.1	$\text{OCO}(\text{CH}_2)_n\text{CH}(\text{OH})\text{CH}_2\text{Q}$
CJ 9	OCOC_6H_5
CJ 10	as identified in the application as FIG. 1b
CJ 11	$\text{YCO}(\text{CH}_2)_n\text{COQ}$;

and wherein n is an integer, and Q is the carrier.

Claim 101 (new): A hapten-carrier conjugate according to claim 100, wherein n is from about 2 to about 20.

Claim 102 (new): A hapten-carrier conjugate according to claim 100, wherein Y is selected from the group consisting of S, O and NH.

Claim 103 (new): A hapten-carrier conjugate according to claim 100, wherein the carrier is selected from:- proteins or peptides, bacterial toxins or products, subvirals, lectins, allergens and fragments of allergens, malarial protein antigen, artificial multi-antigenic peptides, and modifications, analogs and derivatives thereof.

Claim 104 (new): The hapten-carrier conjugate of claim 100, wherein greater than one hapten is coupled to the carrier.

Claim 105 (new): A method of treating nicotine addiction in a mammal comprising administering a therapeutically effective amount of the hapten-carrier conjugate of claim 100 to a subject mammal.

Claim 106 (new): A method according to claim 105, wherein said hapten-carrier conjugate is administered mucosally and comprises co-polymer microspheres optionally of poly(lactide-co-glycolide) co-polymer.

Claim 107 (new): A method according to claim 105, wherein said hapten-carrier conjugate is administered as a topical preparation and which preparation optionally has a dynamic viscosity greater than water.

Claim 108 (new): A method according to claim 105, wherein said hapten-carrier conjugate is administered as an injectible, sterile solution.

Claim 109 (new): A pharmaceutical preparation, which comprises (a) the hapten-carrier conjugate of claim 105, and also (b) adjuvant.

Claim 110 (new): A process for preparing a conjugate according to claim 100, which comprises linking the hapten and the carrier containing a T cell epitope by cross linking with a compound selected from: a carboxylic acid derived active ester, a mixed anhydride, an acyl azide, an acyl halide, an imino ester.